Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol

Aarti Dave; Surohi Shah; Yogin Mistry; Naina Chaturvedi; Disha Jariwala

doi:10.5455/njppp.2022.12.08272202113082021

2026, Vol: 16, Issue: 2

16 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 30 Aug 2021

Natl J Physiol Pharm Pharmacol. 2022; 12(2): 127-131

doi: 10.5455/njppp.2022.12.08272202113082021

Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol

Aarti Dave, Surohi Shah, Yogin Mistry, Naina Chaturvedi, Disha Jariwala.

Cited By:4

Abstract
Background: India is among the largest countries to implement the revised national tuberculosis (TB) control program (RNTCP). Ocular toxicity of ethambutol has been known since 1962. It can be halted with early detection and cessation of the contributing drug.

Aims and Objectives: This study aims to detect early ocular toxicity of ethambutol in TB patients under directly observed treatment strategy (DOTS).

Materials and Methods: This was a prospective cross-sectional study of 30 patients getting AKT including ethambutol along with isoniazid, rifampicin, and pyrazinamide under RNTCP‑DOTS center at a tertiary care hospital. The detailed history, best-corrected visual acuity (BCVA), color vision, fundus examination, visual field, retinal nerve fiber layer (RNFL) thickness, and central subfield macular thickness were carried out in all patients pretreatment and then at the 2nd month of treatment.

Results: The mean age of patient was 44.87 years. Reduced visual acuity from the baseline was noted at the second in 23.33% of the right eyes (P = 0.01) and 30% of the left eyes (P < 0.01). Mean temporal RNFL thickness was significantly reduced from baseline after 2 months of treatment (P = 0.046). No significant difference was observed with color vision and visual fields pre- and post-treatment.

Conclusion: The assessment of BCVA, color vision, visual field, RNFL, and macular thickness is essential at baseline and thereafter at frequent intervals to detect early ethambutol toxicity and probable reversible visual loss.

Key words: Ethambutol; Retinal Nerve Fiber Layer; Color Vision; Visual Field

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Aarti Dave Articles by Surohi Shah Articles by Yogin Mistry Articles by Naina Chaturvedi Articles by Disha Jariwala
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol. 2022; 12(2): 127-131.

doi:10.5455/njppp.2022.12.08272202113082021

Web Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. https://www.njppp.com/?mno=105661 [Access: June 27, 2026].

doi:10.5455/njppp.2022.12.08272202113082021

AMA (American Medical Association) Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol. 2022; 12(2): 127-131.

doi:10.5455/njppp.2022.12.08272202113082021

Vancouver/ICMJE Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol. (2022), [cited June 27, 2026]; 12(2): 127-131.

doi:10.5455/njppp.2022.12.08272202113082021

Harvard Style

Dave, A., Shah, . S., Mistry, . Y., Chaturvedi, . N. & Jariwala, . D. (2022) Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol, 12 (2), 127-131.

doi:10.5455/njppp.2022.12.08272202113082021

Turabian Style

Dave, Aarti, Surohi Shah, Yogin Mistry, Naina Chaturvedi, and Disha Jariwala. 2022. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. National Journal of Physiology, Pharmacy and Pharmacology, 12 (2), 127-131.

doi:10.5455/njppp.2022.12.08272202113082021

Chicago Style

Dave, Aarti, Surohi Shah, Yogin Mistry, Naina Chaturvedi, and Disha Jariwala. "Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 127-131.

doi:10.5455/njppp.2022.12.08272202113082021

MLA (The Modern Language Association) Style

doi:10.5455/njppp.2022.12.08272202113082021

APA (American Psychological Association) Style

doi:10.5455/njppp.2022.12.08272202113082021

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article